Skip to main content

Month: December 2020

Corline har beslutat om en fullt ut garanterad företrädesemission om 15 MSEK

DETTA PRESSMEDDELANDE FÅR INTE OFFENTLIGGÖRAS, PUBLICERAS ELLER DISTRIBUERAS, DIREKT ELLER INDIREKT, I ELLER TILL AUSTRALIEN, HONKONG, JAPAN, KANADA, NYA ZEELAND, SINGAPORE, SYDAFRIKA, USA ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN ÅTGÄRD HELT ELLER DELVIS ÄR FÖREMÅL FÖR LEGALA RESTRIKTIONER. DETTA PRESSMEDDELANDE UTGÖR INTE ETT ERBJUDANDE ATT FÖRVÄRVA VÄRDEPAPPER I CORLINE BIOMEDICAL AB. SE ÄVEN AVSNITTET ”VIKTIG INFORMATION” NEDAN.PressmeddelandeCorline Biomedical AB556417-07432020-12-04Styrelsen i Corline Biomedical AB (publ) (“Corline” eller “Bolaget”) har beslutat om nyemission av aktier om 15 MSEK med företrädesrätt för befintliga aktieägare (“Företrädesemissionen”), under förutsättning av godkännande från en extra bolagsstämma den 30 december 2020. Företrädesemissionen är fullt ut säkerställd genom...

Continue reading

Bekaert addresses structural changes in the new market environment

Intention to reorganize activities with an impact on employment in Belgium The impact of the Covid-19 pandemic on economies and demand patterns will have significant lasting effects. In order to meet the changing customer and market requirements as well as ways of working, Bekaert has determined a number of actions to enable the Group to adapt to the new environment.  By addressing these structural changes, the Group will also lay the foundations for new capabilities and sustainable value creation.Bekaert is enhancing the effectiveness of its operating model and process efficiencies across the business. The Group will develop stronger knowledge centers and invest further in shared services to consolidate expertise and activities in business areas that serve the global footprint. This may include decisions to relocate or outsource such...

Continue reading

Bekaert pakt structurele veranderingen in de nieuwe marktomgeving aan

Intentie tot herschikking van activiteiten met impact op tewerkstelling in België De impact van de Covid-19 pandemie zal aanzienlijke blijvende effecten hebben op economieën en vraagpatronen. Om te beantwoorden aan veranderende klanten- en marktverwachtingen en werkwijzen, heeft Bekaert een aantal maatregelen bepaald die de groep in staat zullen stellen zich aan te passen aan deze nieuwe realiteit. Door de structurele veranderingen aan te pakken, wil de groep ook de grondslag leggen voor het opbouwen van nieuwe vaardigheden en duurzame waardecreatie.Bekaert wil de doeltreffendheid van het operating model en de efficiëntie van processen doorheen de business verhogen. De groep zal daartoe sterkere kenniscentra uitbouwen en verder investeren in ‘shared services’ om de expertise en activiteiten te consolideren van businessdomeinen die ondersteunende...

Continue reading

Bekaert aborde les changements structurels liés au nouvel environnement de marché

Intention de redéployer certaines activités avec un impact sur l’emploi en Belgique L’impact de la pandémie de Covid-19 sur les économies et les tendances de demande aura des effets durables importants. Afin de répondre à l’évolution des attentes des clients et du marché ainsi que des méthodes de travail, Bekaert a déterminé un nombre d’actions pour permettre au Groupe de s’adapter au nouvel environnement. En abordant ces changements structurels, le Groupe souhaite également établir les bases de nouvelles compétences et de la création de valeur durable.Bekaert veut améliorer l’efficacité de son modèle opérationnel et l’efficience des processus à travers l’entreprise.Le Groupe développera des centres de connaissances plus forts et investira davantage dans des services partagés afin de consolider l’expertise...

Continue reading

ADDITIONAL ORDERS FROM AXFOOD

Westpay AB, a leading Fintech company, has received new orders for payment terminals and services, as part of ongoing cooperation with Axfood. These orders represent a positive sign of progress in the deployment of next generation payment terminals in Axfood stores. The orders received from Axfood, amount to more than SEK 1 million initially and will be delivered during the fourth quarter of 2020. These orders are in addition to what has been previously communicated.– A project of this magnitude is a good way to benchmark our processes. Having additional orders like this is the best feedback we can get. It proves that we are on track and that our hard work pays off. I am proud of how we, together with them at Axfood, manage to maintain the highest quality, says Tomas Nilsson, CTO at Westpay.In early 2020, Axfood contracted Westpay with...

Continue reading

AB Science announces that confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain was successful

Paris, December 4, 2020, 8.30amAB Science announces that confirmatory Phase 3 study AB12005 with masitinibin first line pancreatic cancer with pain was successful and reached its primaryobjective to show statistically significant increase in survivalAB Science SA (Euronext – FR0010557264 – AB) today announced that its Phase 3 study (AB12005 – NCT03766295) met its primary objective to demonstrate increase in survival in pancreatic cancer with pain.Study AB12005 evaluated masitinib 6.0 mg/kg/day in combination with gemcitabine in first-line treatment of unresectable locally advanced or metastatic pancreatic cancer patients with pain. The study was successful if its primary objective to test a significant increase in overall survival was reached at a 2.5% level of statistical significance in either the overall population...

Continue reading

AB Science annonce que l’étude confirmatoire de phase 3 AB12005 avec le masitinib dans le cancer du pancréas en première ligne avec douleur est positive

Paris, 04 décembre 2020, 8h30AB Science annonce que l’étude confirmatoire de phase 3 AB12005 avec le masitinibdans le cancer du pancréas en première ligne avec douleur est positive et a atteint sonobjectif de démontrer une augmentation statistiquement significative de la survieAB Science SA (Euronext – FR0010557264 – AB) annonce aujourd’hui que son étude de phase 3 (AB12005 – NCT03766295) a atteint son objectif principal de démontrer une augmentation de la survie dans le cancer du pancréas avec douleur.L’étude AB12005 a évalué le masitinib à la dose de 6,0 mg/kg/jour en association avec la gemcitabine dans le traitement en première ligne chez les patients atteints d’un cancer du pancréas avec douleur, non opérable localement avancé ou métastatique. L’objectif principal de l’étude était considéré...

Continue reading

Pharmaceutical Packaging Market to Reach USD 153.93 Billion by 2027; Increasing Technological Advancements and Innovations in Pharmaceutical Packaging Processes to Stimulate Growth, states Fortune Business Insights™

Pune, India, Dec. 04, 2020 (GLOBE NEWSWIRE) — The global pharmaceutical packaging market size is expected to reach USD 153.93 billion by 2027, exhibit a CAGR of 6.4% during the forecast period.  The growing adoption of novel and generic drugs in developing countries will have an excellent impact on the global market, states Fortune Business Insights, in a report, titled “Pharmaceutical Packaging Market Size, Share & COVID-19 Impact Analysis, By Material (Plastics, Glass, Metal, Paper & Paperboard,), By Product (Plastic Bottles, Caps & Closures, Pre-Fillable Inhalers, Pre-Fillable Syringes, Vials & Ampoules, Blister Packs, Bags & Pouches, Jars & Canisters, Cartridges,), By Packaging Type (Primary, Secondary, and Tertiary), By Drug Delivery Mode, and Regional Forecast, 2020-2027.” The market size stood...

Continue reading

Horizonte Minerals Plc: Araguaia Project Operational Update

LONDON, Dec. 04, 2020 (GLOBE NEWSWIRE) — Horizonte Minerals Plc, (AIM: HZM, TSX: HZM) (“Horizonte” or “the Company’) the nickel company focused on Brazil, is pleased to provide an operational update for the Araguaia Nickel Project (“Araguaia” or “the Project”) as the Project moves towards construction.Highlights:Completion of the value engineering phase with improvements made to plant design and flow sheet to optimise operational performance;Capex and opex remain in line with Feasibility Study following comprehensive review;Operational Readiness Plan well advanced with all key permits in place for commencement of construction;Key environmental and social programmes underway in preparation for construction phase;Project finance process continues to progress, with a number of key milestones delivered;Build out of the operational and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.